BiVictriX Therapeutics (LSE:BVX) EBIT per Share : £-0.04 (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is BiVictriX Therapeutics EBIT per Share?

BiVictriX Therapeutics's EBIT per Share for the six months ended in Jun. 2024 was £-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.04.

During the past 3 years, the average EBIT per Share Growth Rate was -73.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was -56.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for BiVictriX Therapeutics's EBIT per Share or its related term are showing as below:

LSE:BVX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -77.8 Med: -77.3 Max: -73.8
Current: -73.8

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of BiVictriX Therapeutics was -73.80% per year. The lowest was -77.80% per year. And the median was -77.30% per year.

LSE:BVX's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.9 vs LSE:BVX: -73.80

BiVictriX Therapeutics's EBIT for the six months ended in Jun. 2024 was £-1.61 Mil.

BiVictriX Therapeutics EBIT per Share Historical Data

The historical data trend for BiVictriX Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiVictriX Therapeutics EBIT per Share Chart

BiVictriX Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.01

-0.05

-0.04

BiVictriX Therapeutics Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial						-0.02	-0.02	-0.02	-0.02	-0.02

BiVictriX Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

BiVictriX Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.025	/	72.645
=	-0.04

BiVictriX Therapeutics's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.609	/	72.645
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.04

BiVictriX Therapeutics (LSE:BVX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

BiVictriX Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of BiVictriX Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BiVictriX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiVictriX Therapeutics PLC (LSE:BVX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Alderley Edge, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.bivictrix.com

BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilizes Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia. The Group has one reportable segment, being the development of pharmaceutical products within the United Kingdom.

BiVictriX Therapeutics Headlines

No Headlines